Slfn2 inhibitors belong to a specialized category of chemical compounds that specifically target and inhibit the activity of Schlafen family member 2 (Slfn2), a protein encoded by the SLFN2 gene. This protein plays a crucial role in various cellular processes, and its inhibition by these compounds can lead to significant alterations in cell behavior. The chemical structure of Slfn2 inhibitors is typically characterized by a high degree of specificity and affinity towards the Slfn2 protein, allowing them to bind effectively and block its activity. These inhibitors are designed to interact with key domains of the Slfn2 protein, often targeting its active sites or regions critical for its structural integrity or interaction with other cellular components.
The development and study of Slfn2 inhibitors involve advanced chemical synthesis and molecular biology techniques. Researchers focus on understanding the molecular interactions between these inhibitors and the Slfn2 protein at a detailed level, often employing techniques such as X-ray crystallography, NMR spectroscopy, and computational modeling. These studies are crucial for refining the inhibitors' design, enhancing their specificity and potency. The molecular structure of Slfn2 inhibitors often includes a variety of functional groups and moieties, which are strategically placed to optimize binding to the Slfn2 protein. These functional groups may include, but are not limited to, aromatic rings, heteroatoms, and hydrogen bond donors or acceptors. The physicochemical properties of these inhibitors, such as solubility, stability, and molecular weight, are also carefully considered during their development, as these factors can significantly impact their interactions with the Slfn2 protein and overall behavior in a cellular context.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12 that inhibits mTOR, a kinase involved in protein synthesis, possibly reducing Slfn2 expression. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase, which could indirectly reduce Slfn2 expression. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, potentially impacting proteins involved in Slfn2 regulation. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A binds to DNA and preferentially inhibits transcription of GC-rich templates, which may include the Slfn2 gene. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits Topoisomerase I, leading to DNA damage and potentially affecting Slfn2 transcription. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C cross-links DNA upon reductive activation, which could hinder Slfn2 gene transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds to DNA and inhibits transcription elongation by RNA polymerase, which could reduce Slfn2 mRNA synthesis. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits cyclin-dependent kinases and might affect cell cycle-related expression of Slfn2. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 inhibits BET bromodomain proteins, affecting transcriptional elongation and potentially decreasing Slfn2 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may alter transcription factor activity, possibly reducing Slfn2 expression. | ||||||